RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DE LUCA A
Collezione ASL Città di Torino

Items : 15

Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells. in The Journal of general virology / J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001499.

2021
ASL Città di Torino

Vicenti I; Dragoni F; Monti M; Trombetta CM; Giannini A; Boccuto A; Saladini F; Rossetti B; De Luca A; Ciabattini A; Pastore G; Medaglini D; Orofino G; Montomoli E; Zazzi M;

Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2021 Feb 22;14(2):171. doi: 10.3390/ph14020171.

2021
ASL Città di Torino
AOU Città della Salute di Torino

Brusa P; De Luca A; Collino M; Ravetto Enri L; Torta R; D'Avolio A; Pignata I; Simiele M; Baratta F;

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? in BMC public health / BMC Public Health. 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1.

2019
ASL Città di Torino

Shanyinde M; Girardi E; Puoti M; De Luca A; Sighinolfi L; Caterina UF; Caramello P; Lampe FC; D'Arminio Monforte A; Cozzi-Lepri A;

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. in Journal of acquired immune deficiency syndromes (1999) / J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986.

2019
ASL Città di Torino

Rossetti B; Gagliardini R; Sterrantino G; Colangeli V; Latini A; Colafigli M; Vignale F; Rusconi S; Di Biagio A; Orofino G; Mezzaroma I; Vullo V; Francisci D; Mastroianni C; Trezzi M; Canovari B; Lamonica S; Ciccullo A; Borghetti A; D?Arminio Monforte A; Di Giambenedetto S; De Luca A;

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. in Journal of the International AIDS Society / J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227.

2019
ASL Città di Torino

Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;

Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes. in Frontiers in pharmacology / Front Pharmacol. 2019 Jun 25;10:701. doi: 10.3389/fphar.2019.00701. eCollection 2019.

2019
ASL Città di Torino
AOU Città della Salute di Torino

D'Avolio A; Brusa P; Collino M; De Luca A; Pignata I; Ravetto Enri L; Torta R; Baratta F; Simiele M;

Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology / Eur J Clin Microbiol Infect Dis. 2018 May;37(5):871-881. doi: 10.1007/s10096-017-3180-8. Epub 2018 J

2018
ASL Città di Torino

Leone S; Shanyinde M; Cozzi Lepri A; Lampe FC; Caramello P; Costantini A; Giacometti A; De Luca A; Cingolani A; Ceccherini Silberstein F; Puoti M; Gori A; d'Arminio Monforte A;

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

2018
ASL Città di Torino

Fabbiani M; Gagliardini R; Ciccarelli N; Quiros Roldan E; Latini A; d'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Del Pin B; Lombardi F; D'Avino A; Focà E; Colafigli M; Cauda R; Di Giambenedetto S; De Luca A;

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America / Clin Infect Dis. 2017 Mar 1;64(5):680-683. doi: 10.1093/cid/ciw846. Epub 2016 Dec 22.

2017
ASL Città di Torino

Massimo A; Teti E; Antinori A; Milazzoi L; Sollima S; Rizzardini G; Di Biagio A; Saracino A; Bruno R; Borghi V; De Luca A; Cattelan A; Hasson H; Taliani G; Monforte AD; Mastroianni CM; Di Perri G; Bigoni S; Puoti M; Spinetti A; Gori A; Boffa N; Bruno C; Giacometti A; Parruti G; Vullo V; Chirianni A; Pennica A; Pasquazzi C; et alii...

Treatment simplification to atazanavir/ritonavir?+?lamivudine versus maintenance of atazanavir/ritonavir?+?two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

2017
ASL Città di Torino

Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. in PloS one / PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

2017
ASL Città di Torino

Rossetti B; Gagliardini R; Meini G; Sterrantino G; Colangeli V; Re MC; Latini A; Colafigli M; Vignale F; Rusconi S; Micheli V; Di Biagio A; Orofino G; Ghisetti V; Fantauzzi A; Vullo V; Grima P; Francisci D; Mastroianni C; Antinori A; Trezzi M; Lisi L; Navarra P; Canovari B; D'Arminio Monforte A; Lamonica S; D'Avino A; Zazzi M; Di Giambenedetto S; et alii...

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. in The new microbiologica / New Microbiol. 2015 Oct;38(4):443-90.

2015
ASL Città di Torino

Andreoni M; Marcotullio S; Puro V; De Carli G; Tambussi G; Nozza S; Gori A; Rusconi S; Santoro MM; Clementi M; Perno CF; d'Arminio Monforte A; Maggiolo F; Castagna A; De Luca A; Galli M; Giacomelli A; Borderi M; Guaraldi G; Calcagno A; Di Perri G; Bonora S; Mussini C; Di Biagio A; Puoti M; Bruno R; Zuccaro V; Antinori A; Cinque P; et alii...

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study. in Journal of the International AIDS Society / J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19818. doi: 10.7448/IAS.17.4.19818. eCollection 2014.

2014
ASL Città di Torino

Gagliardini R; Rossetti B; Bianco C; Rusconi S; Colafigli M; Prinapori R; Francisci D; Fantauzzi A; Orofino G; Vignale F; Di Giambenedetto S; De Luca A;

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. in Journal of the International AIDS Society / J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

2014
ASL Città di Torino

Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;

Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort. in PloS one / PLoS One. 2014 Feb 27;9(2):e89861. doi: 10.1371/journal.pone.0089861. eCollection 2014.

2014
ASL Città di Torino

Cingolani A; Cozzi-Lepri A; Ammassari A; Mussini C; Ursitti MA; Caramello P; Angarano G; Bonfanti P; De Luca A; Mura MS; Girardi E; Antinori A; Monforte AD;